Overview

Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer

Status:
Unknown status
Trial end date:
2019-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well giving aflibercept together with combination chemotherapy works in treating patients with previously untreated colon or rectal cancer that is metastatic or locally advanced and cannot be removed by surgery. Aflibercept may stop the growth of colon or rectal cancer by blocking blood flow to the tumor. Drugs used in chemotherapy, such as leucovorin calcium, fluorouracil, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving aflibercept together with combination chemotherapy may kill more tumor cells
Phase:
Phase 2
Details
Lead Sponsor:
John Hays
Richard Goldberg
Collaborator:
Sanofi
Treatments:
Aflibercept
Endothelial Growth Factors
Fluorodeoxyglucose F18
Fluorouracil
Leucovorin
Oxaliplatin